Rockwell Medical, Inc. (RMTI): Price and Financial Metrics

Rockwell Medical, Inc. (RMTI)

Today's Latest Price: $1.05 USD

0.06 (5.53%)

Updated Nov 27 1:00pm

Add RMTI to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

RMTI Stock Summary

  • With a year-over-year growth in debt of 446.64%, Rockwell Medical Inc's debt growth rate surpasses 95.99% of about US stocks.
  • The volatility of Rockwell Medical Inc's share price is greater than that of 86.12% US stocks with at least 200 days of trading history.
  • Rockwell Medical Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -66.81%, greater than the shareholder yield of only 5.28% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Rockwell Medical Inc are WTT, NSPR, CPIX, RWLK, and PRCP.
  • RMTI's SEC filings can be seen here. And to visit Rockwell Medical Inc's official web site, go to

RMTI Stock Price Chart Interactive Chart >

Price chart for RMTI

RMTI Price/Volume Stats

Current price $1.05 52-week high $3.85
Prev. close $1.00 52-week low $0.83
Day low $1.00 Volume 1,059,700
Day high $1.07 Avg. volume 1,218,372
50-day MA $1.03 Dividend yield N/A
200-day MA $1.81 Market Cap 98.25M

Rockwell Medical, Inc. (RMTI) Company Bio

Rockwell Medical is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. The company was founded in 1995 and is based in Wixom, Michigan.

RMTI Latest News Stream

Event/Time News Detail
Loading, please wait...

RMTI Latest Social Stream

Loading social stream, please wait...

View Full RMTI Social Stream

Latest RMTI News From Around the Web

Below are the latest news stories about Rockwell Medical Inc that investors may wish to consider to help them evaluate RMTI as an investment opportunity.

Robust Growth Visible for Hypercalcemia Treatment Market 2020-2025 | International Key Players - AbbVie, Amgen, Novartis, Rockwell Medical

Global Hypercalcemia Treatment Market Overview: The Hypercalcemia Treatment Market has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Hypercalcemia Treatment Market size to maintain the average annual growth rate of 5.42% from $169

OpenPR | September 29, 2020

Rockwell Medical announces $35M direct offering

Rockwell Medical (RMTI) enters into securities purchase agreements with several healthcare-focused and other institutional investors to purchase ~23M of its shares and short-term warrants.  The combined purchase price for one share of common stock and a warrant is $1.51. The warrants have an exercise price of $1.80 per share, will be...

Seeking Alpha | September 23, 2020

Rockwell Medical gains 15% on Triferic pact in South Korea

Rockwell Medical (RMTI) has entered into an exclusive license agreement with Jeil Pharmaceutical, for the rights to commercialize Triferic in South Korea. Under the terms, Jeil will be the exclusive development and commercialization partner for Triferic in South Korea and Rockwell Medical will supply the product to Jeil. A Joint...

Seeking Alpha | September 9, 2020

Rockwell Medical, Inc. to Present at Upcoming September Investor Conferences

WIXOM, Mich., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) ("Rockwell Medical" or the “Company”), a biopharmaceutical company…

GlobeNewswire | September 8, 2020

The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3) Akouos Inc (NASDAQ: AKUS ) FibroGen Inc (NASDAQ: FGEN )(reacted to an adverse clinical readout for a rival drug to treat chronic kidney disease related anemia) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Sutro Biopharma Inc (NASDAQ: STRO ) ( reacted to announcement concerning presentation of positive data for ovarian cancer drug) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 3) Akebia Therapeutics Inc (NASDAQ: AKBA ) (announced negative safety results for a late-stage study of drug to treat chronic kidney disease-induced anemia) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Genfit SA (NASDA...

Benzinga | September 4, 2020

Read More 'RMTI' Stories Here

RMTI Price Returns

1-mo 20.72%
3-mo -20.45%
6-mo -49.76%
1-year -53.95%
3-year -83.20%
5-year -91.34%
YTD -56.97%
2019 7.96%
2018 -61.17%
2017 -11.15%
2016 -36.04%
2015 -0.39%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9662 seconds.